Betta Other Liab vs Accounts Payable Analysis

300558 Stock

49.36 3.74 7.04%

Betta Pharmaceuticals financial indicator trend analysis is way more than just evaluating Betta Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Betta Pharmaceuticals is a good investment. Please check the relationship between Betta Pharmaceuticals Other Liab and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Betta Pharmaceuticals Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Other Liab vs Accounts Payable

Other Liab vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Betta Pharmaceuticals Other Liab account and Accounts Payable. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Betta Pharmaceuticals' Other Liab and Accounts Payable is 0.8. Overlapping area represents the amount of variation of Other Liab that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Betta Pharmaceuticals Co, assuming nothing else is changed. The correlation between historical values of Betta Pharmaceuticals' Other Liab and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Liab of Betta Pharmaceuticals Co are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Other Liab i.e., Betta Pharmaceuticals' Other Liab and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.8

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Other Liab

Accounts Payable

An accounting item on the balance sheet that represents Betta Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Betta Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Betta Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Betta Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Betta Pharmaceuticals Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

As of November 25, 2024, Selling General Administrative is expected to decline to about 632.6 M. The current year's Tax Provision is expected to grow to about (11 M)

	2021	2022	2023	2024 (projected)
Operating Income	381.4M	208.4M	332.1M	285.1M
Total Revenue	2.2B	2.4B	2.5B	1.4B

Operating Income Total Revenue

Betta Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Accounts Payable	Cash	Other Assets	Long Term Debt	Net Receivables	Short Term Investments	Inventory	Other Current Assets	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Retained Earnings	Net Tangible Assets	Other Stockholder Equity	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Total Current Assets	Short Term Debt	Non Current Assets Total
Total Assets		-0.26	0.94	0.98	0.94	0.93	0.71	0.91	0.91	0.89	-0.14	0.98	0.94	0.96	0.99	0.66	0.97	0.88	0.86	0.92	0.96	-0.75	0.81	0.78	0.83	0.93
Other Current Liab	-0.26		-0.46	-0.15	-0.02	-0.54	0.24	0.04	-0.29	-0.5	0.24	-0.29	-0.11	-0.4	-0.23	0.12	-0.2	0.05	-0.04	-0.21	-0.08	-0.02	0.21	-0.05	0.15	-0.24
Total Current Liabilities	0.94	-0.46		0.88	0.84	0.94	0.52	0.82	0.84	0.95	-0.27	0.95	0.85	0.97	0.93	0.53	0.91	0.76	0.73	0.84	0.87	-0.68	0.7	0.64	0.72	0.91
Total Stockholder Equity	0.98	-0.15	0.88		0.93	0.88	0.79	0.9	0.85	0.86	-0.04	0.97	0.93	0.9	0.97	0.72	0.97	0.93	0.91	0.9	0.96	-0.74	0.86	0.85	0.87	0.91
Other Liab	0.94	-0.02	0.84	0.93		0.8	0.8	0.97	0.88	0.76	-0.2	0.91	0.93	0.89	0.95	0.59	0.88	0.87	0.85	0.95	0.99	-0.86	0.84	0.78	0.84	0.89
Accounts Payable	0.93	-0.54	0.94	0.88	0.8		0.48	0.75	0.89	0.91	-0.26	0.92	0.88	0.95	0.93	0.47	0.9	0.71	0.72	0.85	0.85	-0.6	0.59	0.65	0.63	0.87
Cash	0.71	0.24	0.52	0.79	0.8	0.48		0.78	0.55	0.49	-0.04	0.71	0.67	0.55	0.72	0.64	0.65	0.85	0.88	0.72	0.81	-0.77	0.77	0.85	0.77	0.71
Other Assets	0.91	0.04	0.82	0.9	0.97	0.75	0.78		0.84	0.7	-0.18	0.89	0.91	0.87	0.92	0.63	0.88	0.87	0.8	0.87	0.97	-0.91	0.91	0.7	0.91	0.88
Long Term Debt	0.91	-0.29	0.84	0.85	0.88	0.89	0.55	0.84		0.7	-0.22	0.83	0.87	0.95	0.91	0.49	0.85	0.69	0.68	0.87	0.88	-0.69	0.62	0.59	0.67	0.82
Net Receivables	0.89	-0.5	0.95	0.86	0.76	0.91	0.49	0.7	0.7		-0.15	0.93	0.79	0.88	0.87	0.53	0.88	0.74	0.75	0.81	0.79	-0.56	0.64	0.72	0.65	0.86
Short Term Investments	-0.14	0.24	-0.27	-0.04	-0.2	-0.26	-0.04	-0.18	-0.22	-0.15		-0.16	-0.19	-0.27	-0.24	0.35	-0.07	0.04	0.05	-0.14	-0.22	0.21	0.11	0.17	0.09	-0.26
Inventory	0.98	-0.29	0.95	0.97	0.91	0.92	0.71	0.89	0.83	0.93	-0.16		0.93	0.93	0.98	0.64	0.96	0.89	0.87	0.91	0.95	-0.76	0.81	0.81	0.82	0.94
Other Current Assets	0.94	-0.11	0.85	0.93	0.93	0.88	0.67	0.91	0.87	0.79	-0.19	0.93		0.89	0.96	0.61	0.95	0.86	0.8	0.89	0.95	-0.77	0.8	0.7	0.82	0.89
Total Liab	0.96	-0.4	0.97	0.9	0.89	0.95	0.55	0.87	0.95	0.88	-0.27	0.93	0.89		0.96	0.53	0.92	0.75	0.73	0.88	0.91	-0.71	0.69	0.63	0.73	0.91
Intangible Assets	0.99	-0.23	0.93	0.97	0.95	0.93	0.72	0.92	0.91	0.87	-0.24	0.98	0.96	0.96		0.6	0.96	0.87	0.85	0.93	0.98	-0.78	0.79	0.77	0.81	0.94
Common Stock	0.66	0.12	0.53	0.72	0.59	0.47	0.64	0.63	0.49	0.53	0.35	0.64	0.61	0.53	0.6		0.72	0.79	0.66	0.49	0.61	-0.51	0.75	0.57	0.77	0.62
Property Plant Equipment	0.97	-0.2	0.91	0.97	0.88	0.9	0.65	0.88	0.85	0.88	-0.07	0.96	0.95	0.92	0.96	0.72		0.9	0.82	0.84	0.92	-0.69	0.84	0.73	0.86	0.91
Retained Earnings	0.88	0.05	0.76	0.93	0.87	0.71	0.85	0.87	0.69	0.74	0.04	0.89	0.86	0.75	0.87	0.79	0.9		0.94	0.79	0.9	-0.79	0.92	0.84	0.95	0.9
Net Tangible Assets	0.86	-0.04	0.73	0.91	0.85	0.72	0.88	0.8	0.68	0.75	0.05	0.87	0.8	0.73	0.85	0.66	0.82	0.94		0.85	0.87	-0.76	0.82	0.95	0.85	0.88
Other Stockholder Equity	0.92	-0.21	0.84	0.9	0.95	0.85	0.72	0.87	0.87	0.81	-0.14	0.91	0.89	0.88	0.93	0.49	0.84	0.79	0.85		0.93	-0.79	0.7	0.83	0.72	0.86
Deferred Long Term Liab	0.96	-0.08	0.87	0.96	0.99	0.85	0.81	0.97	0.88	0.79	-0.22	0.95	0.95	0.91	0.98	0.61	0.92	0.9	0.87	0.93		-0.85	0.85	0.8	0.86	0.92
Long Term Investments	-0.75	-0.02	-0.68	-0.74	-0.86	-0.6	-0.77	-0.91	-0.69	-0.56	0.21	-0.76	-0.77	-0.71	-0.78	-0.51	-0.69	-0.79	-0.76	-0.79	-0.85		-0.8	-0.65	-0.83	-0.81
Short Long Term Debt	0.81	0.21	0.7	0.86	0.84	0.59	0.77	0.91	0.62	0.64	0.11	0.81	0.8	0.69	0.79	0.75	0.84	0.92	0.82	0.7	0.85	-0.8		0.73	0.98	0.78
Total Current Assets	0.78	-0.05	0.64	0.85	0.78	0.65	0.85	0.7	0.59	0.72	0.17	0.81	0.7	0.63	0.77	0.57	0.73	0.84	0.95	0.83	0.8	-0.65	0.73		0.73	0.74
Short Term Debt	0.83	0.15	0.72	0.87	0.84	0.63	0.77	0.91	0.67	0.65	0.09	0.82	0.82	0.73	0.81	0.77	0.86	0.95	0.85	0.72	0.86	-0.83	0.98	0.73		0.85
Non Current Assets Total	0.93	-0.24	0.91	0.91	0.89	0.87	0.71	0.88	0.82	0.86	-0.26	0.94	0.89	0.91	0.94	0.62	0.91	0.9	0.88	0.86	0.92	-0.81	0.78	0.74	0.85

Click cells to compare fundamentals

Betta Pharmaceuticals Account Relationship Matchups

Betta Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	4.1B	5.2B	6.3B	7.9B	9.1B	9.6B
Other Current Liab	148.2M	136.9M	95.8M	1.6M	4.1M	3.9M
Total Current Liabilities	705.2M	438.1M	888.9M	2.1B	1.8B	1.9B
Total Stockholder Equity	2.5B	4.1B	4.6B	4.8B	5.3B	5.5B
Other Liab	227.3M	678.9M	644.6M	690.4M	794.0M	833.7M
Accounts Payable	29.2M	113.6M	431.2M	591.0M	800.1M	840.1M
Cash	521.3M	1.3B	792.0M	731.3M	752.0M	466.3M
Other Assets	1.1B	1.5B	1.3B	1.3B	1.5B	1.6B
Net Receivables	57.7M	52.6M	214.1M	433.3M	286.4M	300.7M
Inventory	134.6M	188.6M	293.3M	372.2M	327.5M	343.9M
Other Current Assets	78.7M	63.9M	153.5M	93.8M	140.4M	147.4M
Total Liab	1.7B	1.1B	1.6B	3.0B	3.8B	4.0B
Intangible Assets	1.4B	1.8B	2.4B	2.7B	3.2B	3.3B
Property Plant Equipment	815.1M	789.9M	775.7M	1.3B	1.5B	1.6B
Retained Earnings	1.4B	1.9B	2.1B	2.0B	2.3B	1.2B
Net Tangible Assets	1.3B	1.5B	3.1B	3.0B	3.4B	2.0B
Other Stockholder Equity	4.3M	51.9M	52.3M	74.6M	85.8M	90.1M
Deferred Long Term Liab	565.5M	913.1M	1.2B	1.3B	1.4B	1.5B
Total Current Assets	792.2M	1.8B	1.7B	1.7B	1.5B	1.3B
Non Current Assets Total	3.3B	3.4B	4.6B	6.2B	7.6B	4.3B
Non Currrent Assets Other	1.4M	50.8M	1.1M	6.6M	16.5M	15.7M
Non Current Liabilities Total	958.9M	647.2M	696.8M	847.7M	2.0B	2.1B
Net Invested Capital	3.1B	4.1B	4.6B	5.9B	7.4B	4.8B
Net Working Capital	87.0M	1.4B	765.1M	(371.9M)	(277.3M)	(263.4M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Other Information on Investing in Betta Stock

Balance Sheet is a snapshot of the financial position of Betta Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Betta Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Betta Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Betta currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Betta Other Liab vs Accounts Payable Analysis

Other Liab vs Accounts Payable

Other Liab vs Accounts Payable Correlation Analysis

Correlation Coefficient

Other Liab

Accounts Payable

Betta Pharmaceuticals fundamental ratios Correlations

Betta Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Betta Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Other Information on Investing in Betta Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Intangible Assets	+ 0.99	Total Assets
Deferred Long Term Liab	+ 0.99	Other Liab
Total Stockholder Equity	+ 0.98	Total Assets
Inventory	+ 0.98	Total Assets
Intangible Assets	+ 0.98	Inventory
Deferred Long Term Liab	+ 0.98	Intangible Assets

Long Term Investments	- 0.91	Other Assets
Long Term Investments	- 0.86	Other Liab
Long Term Investments	- 0.85	Deferred Long Term Liab
Short Term Debt	- 0.83	Long Term Investments
Non Current Assets Total	- 0.81	Long Term Investments
Short Long Term Debt	- 0.8	Long Term Investments